<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virulence</journal-id><journal-id journal-id-type="iso-abbrev">Virulence</journal-id><journal-id journal-id-type="publisher-id">KVIR</journal-id><journal-id journal-id-type="publisher-id">kvir20</journal-id><journal-title-group><journal-title>Virulence</journal-title></journal-title-group><issn pub-type="ppub">2150-5594</issn><issn pub-type="epub">2150-5608</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32375558</article-id><article-id pub-id-type="publisher-id">1760443</article-id><article-id pub-id-type="doi">10.1080/21505594.2020.1760443</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages</article-title><alt-title alt-title-type="running-authors">S. AQUARO ET AL.</alt-title><alt-title alt-title-type="running-title">VIRULENCE</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aquaro</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Borrajo</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="AFF0002"><sup>b</sup></xref><xref ref-type="aff" rid="AFF0003"><sup>c</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Pellegrino</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Svicher</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="AFF0002"><sup>b</sup></xref></contrib><aff id="AFF0001"><label>a</label><institution>Department of Pharmacy, Health and Nutritional Sciences, University of Calabria</institution>, Rende, <country>Italy</country></aff><aff id="AFF0002"><label>b</label><institution>Department of Experimental Medicine, University of Rome Tor Vergata</institution>, Roma, <country>Italy</country></aff><aff id="AFF0003"><label>c</label><institution>Department of Microbiology and Parasitology, Faculty of Pharmacy, Complutense University of Madrid</institution>, Madrid, <country>Spain</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Stefano Aquaro <email xlink:href="aquaro@uniroma2.it">aquaro@uniroma2.it</email>; Ana Borrajo <email xlink:href="ana.borrajo@hotmail.com">ana.borrajo@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>6</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><issue>1</issue><fpage seq="34">400</fpage><lpage>413</lpage><history><date date-type="received"><day>12</day><month>10</month><year>2019</year></date><date date-type="rev-recd"><day>12</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="kvir-11-01-1760443.pdf"/><abstract><title>ABSTRACT</title><p>Ongoing with current combinations of antiretroviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection can successfully maintain long-term suppression of HIV-1 replication in plasma. Still, none of these therapies is capable of extinguishing the virus from the long-lived cellular reservoir, including monocyte-derived macrophages (MDM), that means the principal obstacle to HIV cure. MDM are widely distributed in all tissues and organs, including central system nervous (CNS) where they represent the most frequent HIV-infected cells that means the principal obstacle to HIV cure. Current FDA-approved antiretroviral drugs target viral reverse transcriptase, protease, integrase, and entry processes (coreceptor or fusion blockade). It is desirable to continue to develop new antiretrovirals directed against alternative targets in the virus lifecycle in order to further optimize therapeutic options, overcome resistance to existing medications, and potentially contribute to the elimination of viral reservoirs.</p><p>This review provides a comprehensive overview of the activity of antiretroviral drugs (classical and upcoming) in monocytes-derived macrophages (MDM). Defining the antiviral activity of these drugs in this important cellular HIV-1 reservoir provides crucial hints about their efficacy in HIV-1 infected patients.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>HIV-1</kwd><kwd>macrophages</kwd><kwd>virus reservoir</kwd><kwd>antiretroviral drugs target</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">GAIN (Agencia Gallega de Innovaci&#x000f3;n)</named-content><named-content content-type="funder-identifier">10.13039/501100010769</named-content></funding-source><award-id>IN606B-2016/012</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">PRIN (Progetti di Rilevante Interesse Nazionale)</named-content></funding-source><award-id>2015W729WH_ 007</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Conseller&#x000ed;a de Cultura, Educaci&#x000f3;n e Ordenaci&#x000f3;n Universitaria e a Conseller&#x000ed;a de Econom&#x000ed;a, Emprego e Industria (Xunta de Galicia), Spain and by CAM (Comunidad Aut&#x000f3;noma de Madrid)</named-content></funding-source><award-id>2017M8R7N9_004</award-id></award-group><funding-statement>This work was supported by PRIN (Progetti di Rilevante Interesse Nazionale) Grant 2015W729WH_007 and 2017M8R7N9_004 from the MIUR, Italy, by GAIN (Agencia Gallega de Innovaci&#x000f3;n) Grant IN606B-2016/012 from the Conseller&#x000ed;a de Cultura, Educaci&#x000f3;n e Ordenaci&#x000f3;n Universitaria e a Conseller&#x000ed;a de Econom&#x000ed;a, Emprego e Industria (Xunta de Galicia), Spain and by CAM (Comunidad Aut&#x000f3;noma de Madrid) Grant 2019-T2/BIO-12780 from the Consejer&#x000ed;a de Ciencia, Universidades e Innovaci&#x000f3;n.</funding-statement></funding-group><counts><fig-count count="1"/><ref-count count="121"/><page-count count="14"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>The AIDS-related mortality has dropped sharply, and AIDS has gradually become a controllable, chronic disease. Thanks to a highly effective antiretroviral therapy. Based on global AIDS response progress report, there are nearly 17 million people receiving antiretroviral therapy in 2016 [<xref rid="CIT0001">1</xref>] and this number could reach 24 million by 2020.</p><p>The development of drugs for human immunodeficiency virus (HIV) infection began soon after the virus was discovered 25&#x000a0;years ago [<xref rid="CIT0002">2</xref>]. When used daily as prescribed, combined antiretroviral therapy (cART) (usually based on the administration of three drugs) suppresses HIV replication and thus limits disease progression. As a consequence, HIV-infected patients are now expected to live to an old age as long as an oral HIV drug regimen can be continued. Thus, cART has transformed HIV from a terminal illness to a chronic disease [<xref rid="CIT0003">3</xref>].</p><p>Despite this success, the eradication of HIV from the body is not achievable, and the main reason is the presence of virus reservoirs. Monocyte-derived macrophages (MDM) are one of the major cellular targets for HIV-1 infection and an important virus reservoir. MDM contribute to the transmission and the pathogenesis of HIV-1 infection throughout the progression of HIV-1 infection, especially at late stages when CD4&#x02af9; T lymphocytes have been depleted extensively [<xref rid="CIT0004">4</xref>&#x02013;<xref rid="CIT0008">8</xref>].</p><p>HIV-infected MDM are frequently found in the blood and generally distributed in all tissues, organ, and compartments [<xref rid="CIT0007">7</xref>,<xref rid="CIT0008">8</xref>]. In the central nervous system (CNS), MDM and microglia cells represent the most common cell lineages that support virus replication, thus being responsible for the onset of HIV-associated dementia and the neuropathological features of HIV encephalitis [<xref rid="CIT0007">7</xref>&#x02013;<xref rid="CIT0010">10</xref>].</p><p>Tissue macrophages are critical contributors to HIV pathogenesis, however, their specific role in HIV persistence during long-term suppressive ART has been demonstrated by Honeycutt et al. [<xref rid="CIT0011">11</xref>]. In this work, using humanized myeloid-only mice, it was shown that HIV infection of tissue macrophages is rapidly suppressed by ART, as reflected by a rapid drop in plasma viral load and a dramatic decrease in the levels of cell-associated viral RNA and DNA. No viral rebound was observed in the plasma of the ART-treated animals at 7&#x000a0;weeks after ART interruption, and no replication-competent virus was rescued from the tissue macrophages obtained from these animals. In contrast, in a subset of animals, a delayed viral rebound was observed that is consistent with the establishment of persistent infection in tissue macrophages. These observations represent the first direct evidence, to our knowledge, of HIV persistence in tissue macrophages <italic>in vivo</italic> [<xref rid="CIT0011">11</xref>].</p><p>On this basis, we reviewed the activity of antiviral compounds of clinical interest, as well as the factors affecting their efficacy. The current studies consider the relevance of knowing new therapeutic strategies able to prevent HIV-1 replication in MDM, focusing also the attention on current and original compounds. Thus, new and innovative anti-HIV-1 therapeutic approaches directed to HIV-1-infected MDM are briefly described.</p></sec><sec id="S0002"><title>Cellular HIV-1 reservoirs and HIV latency in monocytes/macrophages</title><p>Monocytes are bone marrow-derived mononuclear phagocyte cells that circulate in the blood for few hours/days before being recruited into tissues [<xref rid="CIT0009">9</xref>,<xref rid="CIT0010">10</xref>,<xref rid="CIT0012">12</xref>]. The expression of various chemokine receptors and cell adhesion molecules at their surface allows them to exit the bone marrow into the blood and to be subsequently recruited from the blood into tissues [<xref rid="CIT0009">9</xref>,<xref rid="CIT0011">11</xref>].</p><p>Monocytes represent approximately 10% of leukocytes in the human peripheral blood, with a considerable pool located in the spleen and lungs, as well as homing into inflammatory sites in response to specific chemokines [<xref rid="CIT0010">10</xref>]. Monocytes belong to the innate arm of the immune system providing responses against viral, bacterial, fungal, or parasitic infections [<xref rid="CIT0009">9</xref>,<xref rid="CIT0013">13</xref>]. Their functions include the killing of pathogens via phagocytosis, the production of reactive oxygen species (ROS), nitric oxide (NO), myeloperoxidase, and inflammatory cytokines [<xref rid="CIT0013">13</xref>]. Under specific conditions, monocytes can stimulate or inhibit T-cell responses during cancer as well as infectious and autoimmune diseases. They are also involved in tissue repair and neovascularization [<xref rid="CIT0014">14</xref>].</p><p>The failure of cART in eradicating HIV infection has underlined the relevance of the presence of HIV-1 reservoirs in the body. HIV-1 can evade immune response by several mechanisms, including the establishment of persistent infection within different cell types, including memory or naive T lymphocytes and MDM. In particular, MDM represent an important HIV-1 cellular reservoir as they can survive to HIV-1 cytopathic effect for prolonged periods of time (particularly microglia or alveolar macrophages) [<xref rid="CIT0015">15</xref>&#x02013;<xref rid="CIT0022">22</xref>], thus allowing HIV-1 spreading into anatomical sanctuaries.</p><p>Studies demonstrated that HIV-1 can be detected in circulating monocytes from patients on cART for prolonged periods of time [<xref rid="CIT0023">23</xref>&#x02013;<xref rid="CIT0025">25</xref>]. Interestingly, these monocytes had produced undetectable amounts of HIV-1 RNA under basal conditions, but the virus can reactivate following appropriate stimulation [<xref rid="CIT0023">23</xref>,<xref rid="CIT0025">25</xref>].</p><p>Another key feature of macrophages is represented by their capability to spread the virus to CD4&#x000a0;+&#x000a0;T cells. MDM HIV-infected have been shown to fuse with autologous and heterologous CD4&#x000a0;+&#x000a0;T cells thus allowing HIV-1 transmission to these cells [<xref rid="CIT0025">25</xref>&#x02013;<xref rid="CIT0027">27</xref>].</p><p>HIV-1 replication in macrophages is regulated by cytokines and other extracellular stimuli. Based on the stimuli or cytokine profile, macrophages can be polarized into either M1 (classically activated) or M2 (alternatively activated) [<xref rid="CIT0028">28</xref>,<xref rid="CIT0029">29</xref>]. Cassol and colleagues reported that M1/M2 polarization of MDMs was associated with poor CCR5-dependent HIV-1 infection as compared to non-polarized MDMs.</p></sec><sec id="S0003"><title>Historical background of antiretroviral therapy</title><p>Antiretroviral drugs act by interfering with vital viral replication processes and are classified according to the step they inhibit in the viral life-cycle (<xref rid="F0001">Figure 1</xref>). A sub-classification may be based on their chemical structure. A milestone in the history of HIV disease has been the availability of new classes of drugs, in 1995&#x02013;96, allowing the introduction of combination ARV therapy (HAART) and the gradual evolution of HIV infection into a chronical, usually nonfatal condition [<xref rid="CIT0030">30</xref>,<xref rid="CIT0031">31</xref>]. Currently, there are seven categories of ARV drugs: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase inhibitors (NNRTIs), Protease Inhibitors (PIs), drugs that interfere with viral entry (Fusion Inhibitors [FI] and CCR5 antagonists like maraviroc), Integrase Inhibitors (INIs) and Maturation Inhibitors (MI, in late-stage clinical trial).</p><p>Also, Integrase strand transfer inhibitors (INSTIs) are the class of ARV drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block the strand transfer reaction catalyzed by HIV-1 integrase and have been shown to potently inhibit infection by wild-type HIV-1. The new INSTIs, Bictegravir (BIC), are currently in late-stage clinical trial [<xref rid="CIT0031">31</xref>].</p><p>There is an important topic about the ARV drug tissue penetration. In a recent study, it was shown that for many commonly used ARVs, drug penetration was lower in lymphoid tissue cells than that observed in blood cells [<xref rid="CIT0032">32</xref>]. These findings &#x02013; that measuring drug concentrations in plasma or in PBMCs does not predict those in lymphoid compartments where most viral replication actually occurs and that viral replication persists in the lymphatic tissue of some patients &#x02013; provide a compelling case and rationale to develop new ART strategies that will fully suppress virus production at its source [<xref rid="CIT0032">32</xref>]. In this way, the long-term consequences of persistent virus production for reservoir replenishment and tissue pathologies that restrict immune reconstitution can be averted, and the foundations can be laid for a potential functional cure for HIV-1 infection.</p><p>Because many of antiretroviral drugs belong to the same drug class, if HIV becomes resistant to one drug in a class, it may have varying degrees of resistance to other drugs in the same family. This is called cross-resistance and it can limit future treatment options. Cross-resistance highlights the need for new effective therapies.
<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/21505594.2020.1760443-F0001</object-id><label>Figure 1.</label><caption><p>Schematic representation of steps of HIV-1 life cycle and targets of the currently available antiretroviral drugs.</p></caption><graphic specific-use="web-only" content-type="color" xlink:href="kvir-11-01-1760443-g001"/></fig></p></sec><sec id="S0004"><title>Inhibitors that target the retroviral enzyme reverse transcriptase (RT)</title><p>Inhibitors that target the HIV-1 reverse transcriptase (RT) enzyme hav&#x000a0;played an indispensable role in the treatment and prevention of HIV-1 infection. They can be grouped into two distinct therapeutic groups, namely the nucleoside and nucleotide RT inhibitors (NRTIs), and the non-nucleoside RT inhibitors (NNRTIs). NRTIs form the backbones of most first- and second-line antiretroviral therapy (ART) regimens formulated for the treatment of HIV-1 infection.</p><p>The activity of NRTIs depends on two factors: (1) the intracellular concentration of their triphosphorylated moiety since NRTIs require triphosphorylation by cellular kinases to act as competitors of the natural 2&#x02032; -deoxy-nucleoside trisphosphates (dNTPs); (2) the concentration of the cellular dNTP pools. MDM are resting cells, characterized by a limited DNA synthesis and consequently by a low intracellular level of dNTPs [<xref rid="CIT0011">11</xref>,<xref rid="CIT0030">30</xref>,<xref rid="CIT0031">31</xref>]. The resting status of MDM overcomes the low affinity of most NRTIs for kinases acting at their first phosphorylation step [<xref rid="CIT0011">11</xref>], and results in a competition by dNTPs lower in MDM than in CD4+&#x000a0;lymphocytes whose intracellular dNTPs pool is 6&#x02013;20-fold greater than those found in MDM [<xref rid="CIT0033">33</xref>,<xref rid="CIT0034">34</xref>]. These metabolic characteristics may explain why all the NRTIs clinically available are more active in MDM than in CD4+&#x000a0;lymphocytes in <italic>in vitro</italic> biological models [<xref rid="CIT0011">11</xref>].</p><p>NNRTIs bind to a hydrophobic pocket adjacent to the active site of reverse transcriptase and cause a conformational change that reduces the ability of nucleosides to be added to the growing DNA chain. In general, the NNRTIs have a lower incidence of adverse effects in comparison to the NRTIs. When they were used as single agent, the drugs quickly suppress viral replication, but resistance and virologic relapse soon develop [<xref rid="CIT0035">35</xref>]. With the exception of etravirine and rilpivirine, resistance develops with the substitution of a single amino acid at the NNRTI binding site.</p><p>Since the NNRTI activity is not affected by the dNTP pools, substantial differences in the antiviral activity of NNRTI have not been observed between MDM and CD4+&#x000a0;lymphocytes [<xref rid="CIT0011">11</xref>]. Previous studies confirm these findings, the anti-HIV-1 activity of NNRTIs is not modulated by the macrophage colony-stimulating factor, which increases the dNTPs pool in MDM and thus capable to affect the activity of NRTIs [<xref rid="CIT0033">33</xref>].</p><p>Doravirine (DOR), a novel NNRTI, is active against HIV-1 and the most common NNRTI-resistant variants, and has a favorable, unique, and safety in vitro resistance profile in clinical trials. Because it is not a metabolic inducer or inhibitor [<xref rid="CIT0036">36</xref>,<xref rid="CIT0037">37</xref>], DOR is well absorbed, exhibits moderate protein binding activity and is not a perpetrator of pharmacokinetic drug&#x02013;drug interactions. No clinically meaningful interactions were observed when DOR was co-administered with atorvastatin, oral contraceptives, magnesium-based antacids, or proton-pump inhibitors in healthy volunteers [<xref rid="CIT0036">36</xref>,<xref rid="CIT0038">38</xref>&#x02013;<xref rid="CIT0040">40</xref>]. As a substrate of cytochrome P450 (CYP)3A4, exposure to DOR is reduced in the presence of moderate or strong inducers of CYP3A4 [<xref rid="CIT0036">36</xref>]. It has an elimination half-life of 12&#x02013;21&#x000a0;h. DOR can be taken once daily without regard to food [<xref rid="CIT0036">36</xref>,<xref rid="CIT0041">41</xref>], and its bioavailability is not affected by age, gender, or moderate hepatic impairment [<xref rid="CIT0036">36</xref>,<xref rid="CIT0042">42</xref>,<xref rid="CIT0043">43</xref>]. Drug interaction studies have shown doravirine does not affect the pharmacokinetics of dolutegravir but may have its pharmacokinetics altered by rifampicin (rifampin) and other rifamycins (CYP3A inducers). No clinically significant interactions were noted between doravirine and pantoprazole, ledipasvir/sofosbuvir, or elbasvir/grazoprevir.</p><p>In previous studies, in a phase 2b study in treatment-naive adults, DOR at 100 mg QD with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) demonstrated comparable efficacy to efavirenz with FTC/TDF and had a favorable safety profile, with lower rates of drug-related adverse events and CNS events than efavirenz [<xref rid="CIT0036">36</xref>]. In the phase 3 DRIVE-FORWARD trial, DOR at 100 mg QD demonstrated non-inferior efficacy and a superior lipid profile compared with darunavir-ritonavir after 48&#x000a0;weeks of combination treatment with 2 NRTIs [<xref rid="CIT0044">44</xref>].</p><p>Other researches are needed to better understand doravirine&#x02019;s efficacy and safety profile when co-administered with other agents known to be CYP inducers or inhibitors.</p><p>Also, previous studies postulated that sterile alpha motif- and histidine/aspartic acid domain-containing protein 1 (SAMHD1) limits HIV-1 replication by hydrolyzing deoxynucleoside triphosphates (dNTPs) necessary for reverse transcription [<xref rid="CIT0045">45</xref>]. This report has shown that SAMHD1 cleaves NRTI triphosphates (TPs) at significantly lower rates than dNTPs and that SAMHD1 depletion from monocytic cells affects the susceptibility of HIV-1 infections to NRTIs in complex ways that depend not only on the relative changes in dNTP and NRTI-TP. The presence of SAMHD1, or its depletion, as occurs for lentiviruses that encode the Vpx accessory protein [<xref rid="CIT0046">46</xref>], can affect NRTI susceptibility in multiple ways that depend not only on the relative changes in the concentrations of dNTPs and NRTI-TPs but also on the activation pathways of NRTIs. This work highlights the importance of the metabolic pathways for activation of different NRTIs to NRTI-TPs, especially in cells in which dNTP concentrations are low and competition with NRTI-TPs does not mask the effects of differential NRTI activation.</p><p>SAMHD1 is the dominant host factor controlling post&#x02010;entry permissivity to infection of non&#x02010;dividing MDM. In recent works, it was demonstrated that SAMHD1 phosphorylation status at T592 controlling antiviral activity is naturally dynamic in primary human MDM. Also, the dynamic phosphorylation of SAMHD1 by CDK1 is associated with the expression of proteins typically associated with cell cycle control. Mlcochova et al. have shown that MDM can be stimulated to exit G0 phase and enter a G1&#x02010;like state. This transition with associated CDK1 upregulation and T592 phosphorylation of SAMHD1 renders macrophages permissive to HIV&#x02010;1 [<xref rid="CIT0047">47</xref>].</p><p>Mlcochova et al. have proposed a mechanism where ETO&#x02010;induced DNA damage induces SAMHD1 dephosphorylation via a canonical p53 and p21 pathway in macrophages. As a consequence of this regulation, activated dephosphorylated SAMHD1 mediates a block to HIV&#x02010;1 nuclear import and integration in MDM [<xref rid="CIT0048">48</xref>]. Therefore, topoisomerase inhibitors regulate SAMHD1 and HIV permissivity at a post-RT step, revealing a mechanism by which the HIV-1 reservoir may be limited by chemotherapeutic drugs [<xref rid="CIT0048">48</xref>].</p><p>J&#x000e1;uregui and Landau postulated that the Growth of MDMs under conditions that alter the cell cycle alters SAMHD1 phosphorylation and affects their susceptibility to infection by HIV-1. <italic>In vivo</italic>, MDMs are differentiated as M1, M2. Because MDMs play a role in HIV-1 replication, alterations in SAMHD1 restriction activity could influence HIV-1 replication. While DNA damage agents are not likely to be useful in the treatment of HIV-1 infection, it may be possible to control the SAMHD1 phosphorylation state by targeting intracellular signal transduction in MDMs, thereby reducing virus loads [<xref rid="CIT0049">49</xref>].</p></sec><sec id="S0005"><title>HIV-protease inhibitors</title><p>The PI bind competitively to the substrate site of the viral protease, responsible for the post-translational processing and cleavage of a gag and gag-pol polyprotein during budding from the infected cell. Their potent anti-HIV activity and introduction in clinical use in 1996 was one of the main reasons for the observed substantial falls in morbidity and mortality associated with HIV infection in the developed world [<xref rid="CIT0050">50</xref>].</p><p>HIV PIs prevent cleavage of gag and gag&#x02013;pol poly-protein in acutely and chronically infected cells, arresting maturation and thereby blocking the infectivity of nascent virions [<xref rid="CIT0051">51</xref>]. PIs act during maturation of viral particles in the late stage of HIV-1 life cycle, thus, these drugs can inhibit the release of infectious viral particles from an already infected cell thus preventing subsequent waves of infection. The difference in the anti-HIV-1 activity of PIs in HIV-1 chronically infected MDM and CD4&#x02af9; T lymphocytes may be explained by the high and sustained RNA metabolism in MDM, which affords a great production of virus particles, even from a limited amount of proviral DNA in these cells. Consistent with this hypothesis, HIV-RNA production from chronically infected MDM is not at all affected by PIs, even when protein maturation and release of infectious virus particles are inhibited signi&#x0fb01;cantly [<xref rid="CIT0007">7</xref>]. This may have important clinical implications. In fact, the high concentration of PIs required to suppress HIV-1 replication in chronically infected MDM is often higher than through the PI concentration in plasma of treated patients.</p></sec><sec id="S0006"><title>Integrase inhibitors</title><p>The first INIs were reported approximately 20&#x000a0;years ago [<xref rid="CIT0052">52</xref>]. Approximately 40&#x02013;100 integrase molecules are packaged within each HIV particle. The primary role of integrase is to catalyze the insertion of the viral cDNA into the genome of infected cells, although integrase can also act as a cofactor for reverse transcription [<xref rid="CIT0052">52</xref>&#x02013;<xref rid="CIT0054">54</xref>]. Integration is required for viral replication, because transcription of the viral genome and the production of viral proteins requires that the viral cDNA is fully integrated into a chromosome [<xref rid="CIT0052">52</xref>]. Following reverse transcription, the viral cDNA is primed for integration by integrase-mediated trimming of the 3&#x02032;-ends of the viral DNA [<xref rid="CIT0052">52</xref>]. This step is referred to as 3&#x02032;-PROCESSING. It requires both fully functional integrase and the integrity of the last 10&#x02013;20 base pairs at both ends of the viral cDNA. 3&#x02032;-processing consists of the endonucleolytic cleavage of the 3&#x02032;-ends of the viral DNA. This cleavage occurs immediately 3&#x02032; to a conserved CA dinucleotide motif. Alterations of this sequence prevent integrase from catalyzing 3&#x02032;-processing [<xref rid="CIT0052">52</xref>].</p><p>There are totally three integrase inhibitors [raltegravir (RAL); elvitegravir (EVG); dolutegravir (DTG)], which have been approved by FDA.</p><p>Scopelliti and colleagues have shown that HIV replication is inhibited by INIs in MDM at similar, or even lower, concentrations than those active in PBMCs. This supports the hypothesis that RAL (and other INIs) are able to control the spreading of HIV in MDM and in actively replicating T cells [<xref rid="CIT0055">55</xref>].</p><p>Pollicita et al. have shown that MDMs and PBMCs might act as reservoirs more for wild-type virus than for resistant/low-fitness virus due to a measurable advantage in the replication capacity of wild-type virus compared with RAL-resistant strains in all tested cell systems. Dolutegravir efficiently reduces HIV-1 replication in MDMs, PBMCs, and C8166 cells, with the potential to be effective in different HIV cellular targets, and against RAL-resistant strains harboring the Y143 and N155 mutations [<xref rid="CIT0056">56</xref>].</p><p>Courtney et al. have found that drug penetration for many commonly used ARVs was lower in lymphoid tissue cells than that observed in blood cells. Indeed, in this study, it was shown that measures of virus replication in blood do not necessarily reflect the impact of ARVs on virus production at its principal source in lymphatic compartments. These findings support the hypothesis that ARV concentrations in lymphatic tissue can be insufficient to fully suppress HIV-1 replication and that measuring VL in PB will not necessarily reflect virus production at its source in tissues.</p></sec><sec id="S0007"><title>BIC (Bictegravir)</title><p>In the recent work of Smith and col., based on their antiviral analysis of the ability of these new INIs to inhibit previously identified INIs-resistant single, double, and triple mutants in a single-round replication assay, it appears that BIC is more broadly effective than either of the first-generation INIs, RAL and EVG. In terms of their ability to inhibit INIs-resistant mutants that were tested, BIC was significantly better than DTG [<xref rid="CIT0032">32</xref>]. These conclusions concerning the relative efficacies BIC against mutants are in good agreement with the data of other studies like Yoshinaga et al. [<xref rid="CIT0057">57</xref>] and Neogi et al. [<xref rid="CIT0058">58</xref>]. Based on these results, BIC appears to be a very promising INIs. Nonetheless, based on experience with previous ARV drugs, in the long term, resistant viruses will emerge.</p></sec><sec id="S0008"><title>Entry inhibitors</title><p>The envelope glycoprotein complex (Env) is responsible for the entry of HIV-1 into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. CCR5 antagonists prevent attachment of gp120 to the CCR5 or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. The fusion inhibitors (FIs) target the HIV-1 glycoprotein gp41, thus preventing the fusion between the viral and the host cell membrane. Representative fusion inhibitors include: the first FDA-approved HIV-1 fusion inhibitor T20 (generic name: enfuvirtide; brand name: Fuzeon) [<xref rid="CIT0044">44</xref>,<xref rid="CIT0059">59</xref>], C34, T1249 [<xref rid="CIT0060">60</xref>,<xref rid="CIT0061">61</xref>], T2635 [<xref rid="CIT0062">62</xref>] and sifuvirtide [<xref rid="CIT0063">63</xref>]. It has been demonstrated by using different lab-adapted HIV-1 strains, that T-20 may ef&#x0fb01;ciently prevent the entry of HIV-1 into PBMC, MDM, and immature DC [<xref rid="CIT0064">64</xref>]. It is interesting to note that the T-20 susceptibility may be modulated by coreceptor speci&#x0fb01;city [<xref rid="CIT0065">65</xref>]. In particular, it has been demonstrated that CCR5-using strains are characterized by an intrinsic resistance to T-20, and thus, their replication is suppressed at concentrations of T-20, higher than those required for CXCR4-using strains [<xref rid="CIT0065">65</xref>]. Moreover, the clinical ef&#x0fb01;cacy of T-20 is also strengthened by the fact that the development of drug resistance [<xref rid="CIT0066">66</xref>&#x02013;<xref rid="CIT0069">69</xref>] may be associated with immunological success, despite virological failure [<xref rid="CIT0070">70</xref>].</p><p>A new class of HIV entry inhibitors, CD4 attachment inhibitors, targets the first step of entry. Fostemsavir (FTR) is a small molecule inhibitor that binds HIV envelope glycoprotein 120 (gp120) and prevents virus from binding to the CD4 receptor. It inhibits the entry of HIV into CD4&#x000a0;+&#x000a0;T-lymphocytes by blocking conformational changes in gp120. This mechanism of inhibition is different from that of other entry inhibitors targeting co-receptor binding (maraviroc) or fusion (enfuvirtide). FTR is an oral prodrug of temsavir, the active compound, with potent activity in vitro against HIV, and pharmacokinetics that support once-daily dosing with no need for pharmacologic boosting. Initial clinical investigations have revealed the safety and efficacy of 8-day monotherapy with fostemsavir in HIV-infected individuals [<xref rid="CIT0071">71</xref>,<xref rid="CIT0072">72</xref>]. A Phase IIb study has shown safety, tolerability, and equivalent efficacy of cART including fostemsavir in comparison with a cART including ritonavir-boosted atazanavir in a randomized active-controlled trial [<xref rid="CIT0071">71</xref>,<xref rid="CIT0073">73</xref>,<xref rid="CIT0074">74</xref>].</p><p>The chemokine receptor CCR5 (belonging to the family of the seven-transmembrane domain proteins) is expressed by MDM and represents the most important coreceptor for M-tropic HIV-1 strains to enter the cells. CCR5 plays a crucial role in the transmission of HIV-1 isolates that establish initial infection, persist during the early years of infection, and predominate in brain where HIV causes neuro-AIDS [<xref rid="CIT0073">73</xref>]. Previous studies have shown that TAK-779 is the first non-peptidic molecule known to block selectively the replication of CCR5-using HIV strains in MDM at low concentrations (about 10&#x000a0;nM). TAK779 interacts directly with CCR5 in a specific binding site within the transmembrane domain helices 1, 2, 3, and 7. TAK-779 has a high affinity for CCR5, and totally inactive against CXCR4-using strains of HIV-1 [<xref rid="CIT0073">73</xref>,<xref rid="CIT0075">75</xref>].</p><p>Maraviroc is an allosteric modulator of CCR5 that stabilizes CCR5 in a conformation to which HIV Env does not bind [<xref rid="CIT0076">76</xref>&#x02013;<xref rid="CIT0079">79</xref>]. Maraviroc treatment rarely causes a tropism switch to X4 viral strains in the absence of preexisting X4 strains [<xref rid="CIT0079">79</xref>]. Rather, some cases of maraviroc resistance in R5 HIV strains were reported in vitro and in treated patients. In these instances, HIV evolved the capacity to enter target cells by using the maraviroc-bound form of CCR5 as a coreceptor [<xref rid="CIT0080">80</xref>&#x02013;<xref rid="CIT0082">82</xref>]. Recent clinical trials included maraviroc in an intensified regimen consisting of four or five antiretroviral drugs, with the objective of limiting the establishment of the viral reservoir in acute HIV infection, or of decreasing residual viral replication in chronic HIV infection [<xref rid="CIT0083">83</xref>&#x02013;<xref rid="CIT0088">88</xref>]. Results of such trials have generally been disappointing, as intensified regimen did not prove superiority compared to classic regimens in containing the viral load or in decreasing the HIV reservoir. Unfavorable drug interactions may have limited the benefit of therapy intensification in some cases [<xref rid="CIT0089">89</xref>]. A paradoxical increase in T-cell activation was reported in one trial, possibly due to an increase in the concentration of circulating chemokines [<xref rid="CIT0084">84</xref>]. However, in another trial, maraviroc intensification was associated with an improvement of the CD4 recovery slope in patients with poor immunological restoration [<xref rid="CIT0083">83</xref>]. Surdo M et al., 2013 have shown Maraviroc is effective in-vitro against viruses with dual-characteristics in both MDM and lymphocytes, despite the potential X4-mediated escape [<xref rid="CIT0090">90</xref>]. This suggests that the concept of HIV-entry through one of the two coreceptors &#x0201c;separately&#x0201d; may require revision, and that the use of CCR5 antagonists in patients with dual/mixed-tropic viruses may be a therapeutic option that deserves further investigations in different clinical settings.</p></sec><sec id="S0009"><title>Towards new therapeutic strategies: maturation inhibitors</title><p>Developing inhibitors against novel targets provides a wealth of basic mechanistic information about fundamental aspects of viral replication. A new class of inhibitors is now emerging that targets the internal structural precursor protein, Gag, and its function in the final assembly of the mature, infectious virion, these are the maturation inhibitors (MI). This new class is typified by the compound 3-O-(3&#x002b9;,3&#x002b9;-dimethylsuccinyl)-betulinic acid, known alternatively as Bevirimat (BEV) [<xref rid="CIT0091">91</xref>&#x02013;<xref rid="CIT0093">93</xref>], PA-457 [<xref rid="CIT0092">92</xref>] or DSB [<xref rid="CIT0093">93</xref>]. In this regard, the maturation of HIV-1 particles, which is triggered by the action of the viral PR, occurs concomitantly with virion release from the infected cell [<xref rid="CIT0094">94</xref>&#x02013;<xref rid="CIT0096">96</xref>]. PR cleaves a number of sites in the Gag polyprotein precursor, Pr55Gag, the major structural protein responsible for the formation of virus particles. PR-mediated Gag cleavage gives rise to the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins and to two small spacer peptides, SP1 and SP2, located between CA and NC and between NC and p6, respectively.</p><p>Initially there is rapid cleavage at the C-terminus of SP1, followed by cleavage between MA and CA. Additional cleavage events then occur, with the final (slowest) reaction separating SP1 from the C-terminus of CA [<xref rid="CIT0097">97</xref>]. This final cleavage event is critical in proper virion morphogenesis, as disruption of this cleavage site through mutagenesis leads to aberrant core formation and the generation of noninfectious particles. In the immature particle, the Gag precursor proteins are arranged radially around the outer edge of the virus particle, whereas in the mature virion the CA proteins assemble into a centrally located, conical core (referred to as the capsid) in which the viral RNA genome and the viral enzymes RT and IN reside [<xref rid="CIT0097">97</xref>,<xref rid="CIT0098">98</xref>]. Each processing site within the Gag and Gag-Pol polyprotein precursors is cleaved by PR with distinct kinetics, largely due to the unique primary amino acid sequence at each site [<xref rid="CIT0096">96</xref>]. The consequence of the differential rates of cleavage is that Gag and Gag-Pol processing occurs as a highly ordered cascade of cleavage events. This highly ordered processing is required for proper maturation. Defects in maturation can affect both virus entry [<xref rid="CIT0096">96</xref>,<xref rid="CIT0099">99</xref>] and subsequent postentry events. Even partial disruption of processing at several sites in Gag leads to severely impaired virus infectivity [<xref rid="CIT0096">96</xref>,<xref rid="CIT0100">100</xref>&#x02013;<xref rid="CIT0102">102</xref>], highlighting the utility of Gag processing as a target for antiretrovirals.</p><p>BEV, the first HIV-1 MI, was identified through analyzing natural products coupled with an activity-directed structural modification effort [<xref rid="CIT0092">92</xref>,<xref rid="CIT0093">93</xref>,<xref rid="CIT0103">103</xref>]. BEV, also called PA-457, is a derivative of betulinic acid and has potent antiviral activity against multiple wild-type and drug-resistant clinical HIV-1 isolates. Despite potent activity against HIV-1, this antiretroviral drug is inactive against HIV-2. BEV disrupts a late step in Gag processing involving conversion of the CA precursor (CA-SP1) to mature CA [<xref rid="CIT0092">92</xref>,<xref rid="CIT0093">93</xref>,<xref rid="CIT0103">103</xref>]. Virions from BEV-treated cultures are noninfectious and exhibit an aberrant particle morphology characterized by a spherical, acentric core and a crescent-shaped, electron-dense shell lying just inside the viral membrane. Although BEV specifically disrupts CA-SP1 cleavage, it has been shown that the compound does not affect the viral PR function [<xref rid="CIT0092">92</xref>,<xref rid="CIT0093">93</xref>,<xref rid="CIT0103">103</xref>]. Moreover, consistent with the effect on Gag processing, the determinants of BEV activity map to amino acid residues flanking the Gag CA-SP1 cleavage site [<xref rid="CIT0092">92</xref>,<xref rid="CIT0093">93</xref>,<xref rid="CIT0103">103</xref>&#x02013;<xref rid="CIT0107">107</xref>]. BEV represents a novel class of anti-HIV compounds termed MIs that exploit a previously unidentified viral target.</p><p>In 2009, results from Study 204, a phase II dose-ranging clinical trial, were presented. While not showing impressive antiviral activity, a genotypic test has been developed to predict those most likely to respond to the drug. Later, BEV was renamed bevirimat MPC-4326 and also is developing HIV maturation inhibitors of its own, which are code-named MPC-9055 and MPC-461359. Of these three drugs, MPC-4326 (bevirimat dimeglumine) is the furthest along in clinical development. MPC-4326 was originally developed in a liquid formulation. However, a tablet formulation is now used in clinical trials.</p><p>Results from previous clinical trials of MPC-4326 suggest that the drug is generally well tolerated. Headache is the most common side effect and even this was mild in severity. Many anti-HIV drugs are broken down in the liver or kidneys by different enzymes. An advantage of MPC-4326 is that it is not processed by the more common pathways in the liver that often lead to significant drug&#x02013;drug interactions. MPC-4326 is processed in the liver by the same class of enzymes (called UGTs) that metabolize some other anti-HIV drugs such as RAL (Isentress). Very small portion of MPC-4326 is processed by the kidneys. This means there are few other HIV drugs that will change the way MPC-4326 is processed in the body. Additionally, laboratory studies suggest that MPC-4326 does not inhibit the liver enzyme cytochrome P450 3A4 which processes many anti-HIV drugs. Therefore, there is a low likelihood for MPC-4326 to affect the processing of other anti-HIV drugs and consequently have little impact on the levels of other anti-HIV drugs in the body.</p><p>Mechanism-of-action studies were conducted to ensure that inhibition of maturation was maintained as the inhibitory mechanism. This process led iteratively to the identification of BMS-955176, which contains major structure-activity-directed modifications to elements peripheral to the betulinic acid core structure, as well as to the core itself, compared to BVM. BMS-955176 is a second-generation MI that also inhibits this single, specific HIV-1 <italic>PR</italic> cleavage event between CA and SP1 in <italic>Gag</italic>, producing immature, noninfectious virus particles. However, it exhibits potent activity toward the polymorphic variations in Gag associated with resistance to BVM [<xref rid="CIT0108">108</xref>&#x02013;<xref rid="CIT0110">110</xref>].</p><p>In a previous work, Nowicka-Sans et al. 2016 identified and characterized BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and polymorphic coverage [<xref rid="CIT0108">108</xref>]. In vitro combination studies showed that BMS-955176 MI has a potent in vitro anti-HIV-1 activity and a greatly improved preclinical profile compared to that of bevirimat [<xref rid="CIT0108">108</xref>].</p><p>In our laboratory, projects related to the test of the antiviral capacity of the MI are being carried out. There are ongoing trials in which the antiviral activity of these inhibitors in vitro in macrophages is tested. The research proceeds successfully but still requires more experiments and studies since the results obtained are good but very preliminary.</p></sec><sec id="S0010"><title>Recent strategies and challenges facing delivery of antiretroviral therapies</title><p>Sadowski and Hashemi have observed that the development of a routine effective cure will inevitably require the eradication of these latently infected reservoirs [<xref rid="CIT0111">111</xref>]. Latently infected cells theoretically would be devoid of viral proteins and antigenically indistinguishable from non-infected cells, but some evidence suggests that most latently infected cells produce sporadic occasional viral transcripts, through stochastic mechanisms that may maintain low levels of gene products that could produce a unique cellular identity, either directly or indirectly by affecting the expression of host cell proteins [<xref rid="CIT0112">112</xref>]. Targeting cell receptors on HIV-infected macrophages is an important challenge to the feasibility of most curative strategies for HIV/AIDS. As evidenced by the lack of progress in HIV vaccine development, targeting HIV proteins has been difficult. Host cell surface receptors are more readily targeted regardless of HIV infection status. The major roadblock for targeting macrophages is the limited availability of targeting ligands. Most potential targeting ligands are small-molecule chemicals whereby conjugation to a drug delivery carrier tends to reduce the ability of the ligand to bind to a target cell receptor. Little has been published in this area in general and specifically as it relates to HIV/AIDS. A priority must be put on the discovery of new cell-targeting ligands for potential nanocarriers, their optimal display on drug-loaded nanocarriers.</p><p>Lately, only a few potential cell targets on macrophages have been exploited due to concerns about the potential inference with host immune function or the lack of suitable ligands that can be conjugated to nanocarriers. Most targeting ligands have been peptides as the peptidyl nature makes it amenable to conjugation to a nanocarrier [<xref rid="CIT0113">113</xref>].</p><p>Several and important progress has been made in using human cells as drug delivery depot sites. These approaches have utilized macrophages as drug carriers. HIV drugs were first loaded into nanocarriers [<xref rid="CIT0114">114</xref>] or red blood ghost cells [<xref rid="CIT0115">115</xref>] that become engulfed by macrophages <italic>ex vivo</italic> or <italic>in vivo</italic>. The macrophages then migrated to lymph nodes or additionally to other reticuloendothelial system tissues, acting as a cellular depot in these critical sites of HIV infection where the drugs slowly diffuse out over a period of days to weeks resulting in sustained high local drug concentrations in the lymph nodes or other reticuloendothelial system tissue. In a feline immunodeficiency virus model [<xref rid="CIT0116">116</xref>], the membrane-impermeable HIV drug zalcitabine-TP was first loaded <italic>ex vivo</italic> into autologous red blood cells and the plasma membrane of these red blood cells was then chemically modified so macrophages would recognize and engulf them. In a 7-month experimental feline immunodeficiency virus infection, zalcitabine-loaded erythrocytes protected the majority of peritoneal macrophages and reduced the infection of circulating lymphocytes. The Gendelman group has developed long-acting/extended release nanoformulations of ritonavir, indinavir, and efavirenz (nanoART) [<xref rid="CIT0114">114</xref>]. They reasoned that circulating macrophages traveling across the blood-brain barrier could enhance nanoART brain delivery [<xref rid="CIT0114">114</xref>]. Mechanistic studies [<xref rid="CIT0117">117</xref>] showed that nanoART&#x02013;macrophage interactions enhanced phagocytosis, secretory functions, and cell migration, which could be exploited to increase macrophage nanoART loading capacity. Aouadi et al. [<xref rid="CIT0118">118</xref>] studied anti-inflammatory small interfering RNA (siRNA) delivery utilizing yeast ghost cells. Yeast ghost cells were made by chemical treatment of yeast cell wall so that the cell surface was left with only beta1 3-D-glucan, for which macrophages have a special receptor. siRNA was then loaded into the ghost cells. The ghost cells can be efficiently absorbed orally through M-cells and, once crossed M-cells, avidly phagocytosed by macrophages in the Peyer&#x02019;s Patches. Interestingly, macrophages in the Peyer&#x02019;s Patches were able to migrate into blood circulation and settle at various LNs. Oral gavage of mice with the siRNA-loaded ghost cells containing as little as 20&#x000a0;&#x003bc;g/kg of siRNA directed against tumor necrosis factor alpha (TNF-&#x003b1;) depleted its messenger RNA in macrophages recovered from the peritoneum, spleen, liver and lung, and lowered serum TNF-&#x003b1; levels. Although not developed an HIV application, this approach is readily translatable to the delivery siRNA against HIV infection.</p><p>Also, other recent studies showed that a small population of human macrophages survive acute HIV infection and that these surviving infected cells become latently infected, as viral replication is not detected [<xref rid="CIT0119">119</xref>]. These the surviving cells exhibit metabolic compromise and mitochondrial fusion, lose reliance on Mitochondrial Oxidative Phosphorylation System, and accumulate lipids. Most of these changes could be mimicked by adding succinate or glutamine/glutamate to the cells, supporting a compromised tricarboxylic acid cycle. Despite these changes, no overall alterations in mitochondrial membrane potential or electron transport chain mitochondrial expression were detected. Besides, it was shown that while uninfected macrophages exclusively use glucose and fatty acids as major sources of energy, latently HIV-infected macrophages use glutamine/glutamate as a significant source and gain the capability to shift from one metabolic source to another. Furthermore, blocking the use of glutamate, glutamine, or &#x003b1;-KG results in the specific elimination of HIV surviving reservoirs. Together, these data identify a unique metabolic signature of latently infected cells (not replicated by immune activation), which could be pharmacologically targeted to eliminate HIV reservoirs [<xref rid="CIT0120">120</xref>].</p></sec><sec id="S0011"><title>Conclusions</title><p>Several researches leading to the discovery and progress of HIV inhibitors that are now approved as anti-AIDS drugs are a unique source of information that could, in the future, be used in other attempts of structure-based drug design. Undoubtedly, structural studies are only one part of this complicated procedure. Specific assays of a large ensemble of crystal structures (such as, for example, the HIV PR database) can provide a surprising perspective to the problem of drug&#x02013;target interactions and lead to the design of more efficient drugs. The coupling of such data with other in vitro and in vivo studies makes it possible to enhance the process of design.</p><p>The RTIs and the protease inhibitors are able to inhibit HIV replication in MDM but the limited development of drug resistance suggests that these drugs may efficiently suppress HIV replication in MDM (the main cellular reservoir of HIV infection) for a long time.</p><p>Moreover, the crucial role of MDM as a reservoir in the pathogenesis of HIV infection, especially in the CNS, underlines the importance of testing in MDM the antiviral efficacy of new drugs designed to target different stages of the HIV lifecycle. Particular attention has been dedicated to drugs able to target the CCR5 coreceptor selectively, the main coreceptor used by HIV to enter MDM. The CCR5 antagonists also represent a promising approach for their ability to synergize with T&#x02010;20, the first fusion inhibitor in clinical use [121] even under viral suppression by antiretroviral therapy.</p><p>Taken together, overall findings support the clinical relevance of interfering with HIV replication in MDM. In particular, the inherent properties of HIV infection of MDM should be taken into account in designing therapeutic strategies aimed at achieving an optimal, therapeutic effect in all tissue compartments where the virus hides and replicates. MIs are a new class of HIV drugs with an attractive clinical development profile [<xref rid="CIT0103">103</xref>]. Clinical proof-of-concept demonstrated by the first-in-class MI BEV and reappearance of second-generation drug candidates with improved breadth and potency in clinical trials strongly suggest that in the near future multiple MIs can be approved and used for the treatment of HIV/AIDS patients.</p></sec></body><back><sec id="S0012"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>TC.</given-names></name></person-group>
<article-title>HIV epidemiology and the effects of antiviral therapy on long-term consequences</article-title>. <source>AIDS</source>. <year>2008</year>
<month>9</month>;<volume>22</volume>(<issue>Suppl 3</issue>):<fpage>S7</fpage>&#x02013;<lpage>12</lpage>. <comment>Review</comment>.</mixed-citation></ref><ref id="CIT0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flexner</surname><given-names>C</given-names></name></person-group>
<article-title>HIV drug development: the next 25 years</article-title>. <source>Nat Rev Drug Discov</source>. <year>2007</year>
<month>12</month>;<volume>6</volume>(<issue>12</issue>):<fpage>959</fpage>&#x02013;<lpage>966</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">17932493</pub-id></mixed-citation></ref><ref id="CIT0003"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kraft</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy</article-title>. <source>Eur J Pharm Biopharm</source>. <year>2018</year><month>4</month><day>17</day>
<comment>pii:S0939-6411(18)30157-7</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.ejpb.2018.04.014</pub-id> [<comment>Epub ahead of print</comment>] <comment>Review</comment>.</mixed-citation></ref><ref id="CIT0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomkowicz</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ravyn</surname><given-names>V</given-names></name>, et al</person-group>
<article-title>The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages</article-title>. <source>Blood</source>. <year>2006</year>
<month>8</month>
<day>15</day>;<volume>108</volume>(<issue>4</issue>):<fpage>1145</fpage>&#x02013;<lpage>1150</lpage>. <comment>Epub 2006 Apr 18</comment>.<pub-id pub-id-type="pmid">16621960</pub-id></mixed-citation></ref><ref id="CIT0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbein</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Coaquette</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Perez-Bercoff</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Macrophage activation and HIV infection: can the Trojan horse turn into a fortress?</article-title>
<source>Curr Mol Med</source>. <year>2002</year>
<month>12</month>
<day>2</day>;<volume>8</volume>:<fpage>723</fpage>&#x02013;<lpage>738</lpage>. <comment>Review</comment>.</mixed-citation></ref><ref id="CIT0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquaro</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Svicher</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Schols</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies</article-title>. <source>J Leukoc Biol</source>. <year>2006</year>
<month>11</month>;<volume>80</volume>(<issue>5</issue>):<fpage>1103</fpage>&#x02013;<lpage>1110</lpage>. <comment>Epub 2006 Aug 24. Review</comment>.<pub-id pub-id-type="pmid">16931601</pub-id></mixed-citation></ref><ref id="CIT0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquaro</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Panti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Caroleo</surname><given-names>MC</given-names></name>, et al</person-group>
<article-title>Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes</article-title>. <source>J Leukoc Biol</source>. <year>2000</year>
<month>9</month>;<volume>68</volume>(<issue>3</issue>):<fpage>429</fpage>&#x02013;<lpage>35.8</lpage>.<pub-id pub-id-type="pmid">10985261</pub-id></mixed-citation></ref><ref id="CIT0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perno</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Svicher</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Schols</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Therapeutic strategies towards HIV-1 infection in macrophages</article-title>. <source>Antiviral Res</source>. <year>2006</year>
<month>9</month>;<volume>71</volume>(<issue>2&#x02013;3</issue>):<fpage>293</fpage>&#x02013;<lpage>300</lpage>. <comment>Epub 2006 Jun 9. Review</comment>.<pub-id pub-id-type="pmid">16806514</pub-id></mixed-citation></ref><ref id="CIT0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cihlar</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fordyce</surname><given-names>M</given-names></name></person-group>
<article-title>Current status and prospects of HIV treatment</article-title>. <source>Curr Opin Virol</source>. <year>2016</year>
<month>6</month>;<volume>18</volume>:<fpage>50</fpage>&#x02013;<lpage>56</lpage>. <comment>Epub 2016 Mar 28. Review</comment>.<pub-id pub-id-type="pmid">27023283</pub-id></mixed-citation></ref><ref id="CIT0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-Redondo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fryer</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Bedford</surname><given-names>T</given-names></name>, et al</person-group>
<article-title>Persistent HIV-1 replication maintains the tissue reservoir during therapy</article-title>. <source>Nature</source>. <year>2016</year>
<month>2</month>
<day>4</day>;<volume>530</volume>(<issue>7588</issue>):<fpage>51</fpage>&#x02013;<lpage>56</lpage>. <comment>Epub 2016 Jan 27</comment>.<pub-id pub-id-type="pmid">26814962</pub-id></mixed-citation></ref><ref id="CIT0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honeycutt</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Thayer</surname><given-names>WO</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>CE</given-names></name>, et al</person-group>
<article-title>HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy</article-title>. <source>Nat Med</source>. <year>2017</year>
<month>5</month>;<volume>23</volume>(<issue>5</issue>):<fpage>638</fpage>&#x02013;<lpage>643</lpage>.<pub-id pub-id-type="pmid">28414330</pub-id></mixed-citation></ref><ref id="CIT0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ara&#x000ed;nga</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Edagwa</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mosley</surname><given-names>RL</given-names></name>, et al</person-group>
<article-title>A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy</article-title>. <source>Retrovirology</source>. <year>2017</year>;<volume>14</volume>:<fpage>17</fpage>.<pub-id pub-id-type="pmid">28279181</pub-id></mixed-citation></ref><ref id="CIT0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konvalinka</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kr&#x000e4;usslich</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>M&#x000fc;ller</surname><given-names>B</given-names></name></person-group>
<article-title>Retroviral proteases and their roles in virion maturation</article-title>. <source>Virology</source>. <year>2015</year>
<month>5</month>:<page-range>479&#x02013;480: 403&#x02013;17</page-range>
<comment>Epub 2015 Mar 26. Review</comment> Doi: <pub-id pub-id-type="doi">10.1016/j.virol.2015.03.021</pub-id>.</mixed-citation></ref><ref id="CIT0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wigdahll</surname><given-names>B</given-names></name></person-group>
<article-title>Cellular reservoirs of HIV-1 and their role in viral persistence</article-title>. <source>Curr HIV Res</source>. <year>2008</year>;<volume>6</volume>:<fpage>388</fpage>&#x02013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">18855649</pub-id></mixed-citation></ref><ref id="CIT0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiNapoli</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Ortiz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>F</given-names></name>, et al</person-group>
<article-title>Tissue-resident macrophages can contain replication-competent virus in antiretroviral-naive, SIV-infected Asian macaques</article-title>. <source>JCI Insight</source>. <year>2017</year>
<month>2</month>
<day>23</day>;<volume>2</volume>(<issue>4</issue>):<fpage>e91214</fpage>.<pub-id pub-id-type="pmid">28239657</pub-id></mixed-citation></ref><ref id="CIT0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Summer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>AA</given-names></name>, et al</person-group>
<article-title>The prolonged life-span of alveolar macrophages</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2008</year>
<month>4</month>;<volume>38</volume>(<issue>4</issue>):<fpage>380</fpage>&#x02013;<lpage>385</lpage>. <comment>Epub 2008 Jan 10</comment>.<pub-id pub-id-type="pmid">18192503</pub-id></mixed-citation></ref><ref id="CIT0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnell</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Spudich</surname><given-names>S</given-names></name>, et al</person-group>
<article-title>HIV-1 replication in the central nervous system occurs in two distinct cell types</article-title>. <source>PLoS Pathog</source>. <year>2011</year>
<month>10</month>
<day>7</day>;<volume>10</volume>:<fpage>e1002286</fpage>.</mixed-citation></ref><ref id="CIT0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soulas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Conerly</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>WK</given-names></name>, et al</person-group>
<article-title>Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation</article-title>. <source>Am J Pathol</source>. <year>2011</year>
<month>5</month>;<volume>178</volume>(<issue>5</issue>):<fpage>2121</fpage>&#x02013;<lpage>2135</lpage>.<pub-id pub-id-type="pmid">21514427</pub-id></mixed-citation></ref><ref id="CIT0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gras</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kaul</surname><given-names>M</given-names></name></person-group>
<article-title>Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection</article-title>. <source>Retrovirology</source>. <year>2010</year>
<month>4</month>
<day>7</day>;<volume>7</volume>:<fpage>30</fpage>.<pub-id pub-id-type="pmid">20374632</pub-id></mixed-citation></ref><ref id="CIT0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Satija</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>AM</given-names></name>, et al</person-group>
<article-title>Cell-to-cell spread of HIV and viral pathogenesis</article-title>. <source>Adv Virus Res</source>. <year>2016</year>;<volume>95</volume>:<fpage>43</fpage>&#x02013;<lpage>85</lpage>. <comment>Epub 2016 Apr 4. Review</comment>.<pub-id pub-id-type="pmid">27112280</pub-id></mixed-citation></ref><ref id="CIT0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelchen-Matthews</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kramer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>M</given-names></name></person-group>
<article-title>Infectious HIV-1 assembles in late endosomes in primary macrophages</article-title>. <source>J Cell Biol</source>. <year>2003</year>
<month>8</month>
<day>4</day>;<volume>162</volume>(<issue>3</issue>):<fpage>443</fpage>&#x02013;<lpage>455</lpage>. <comment>Epub 2003 Jul 28</comment>.<pub-id pub-id-type="pmid">12885763</pub-id></mixed-citation></ref><ref id="CIT0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelchen-Matthews</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Raposo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>M</given-names></name></person-group>
<article-title>Endosomes, exosomes and Trojan viruses</article-title>. <source>Trends Microbiol</source>. <year>2004</year>
<month>7</month>;<volume>12</volume>(<issue>7</issue>):<fpage>310</fpage>&#x02013;<lpage>316</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">15223058</pub-id></mixed-citation></ref><ref id="CIT0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raposo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Innes</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Human macrophages accumulate HIV-1 particles in MHC II compartments</article-title>. <source>Traffic</source>. <year>2002</year>
<month>10</month>;<volume>3</volume>(<issue>10</issue>):<fpage>718</fpage>&#x02013;<lpage>729</lpage>.<pub-id pub-id-type="pmid">12230470</pub-id></mixed-citation></ref><ref id="CIT0024"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borrajo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ranazzi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pollicita</surname><given-names>M</given-names></name>, et al</person-group>
<article-title>Effects of amprenavir on HIV-1 maturation, production and infectivity following drug withdrawal in chronically-infected monocytes/macrophages</article-title>. <source>Viruses</source>. <year>2017</year>
<month>9</month>
<day>28</day>;<volume>9</volume>(<issue>10</issue>):<page-range>pii: E277</page-range>.</mixed-citation></ref><ref id="CIT0025"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambotte</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Taoufik</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>de Go&#x000eb;r</surname><given-names>MG</given-names></name>, et al</person-group>
<article-title>Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2000</year>
<month>2</month>
<day>1</day>;<volume>23</volume>(<issue>2</issue>):<fpage>114</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">10737425</pub-id></mixed-citation></ref><ref id="CIT0026"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Muthui</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Holte</surname><given-names>S</given-names></name>, et al</person-group>
<article-title>Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy</article-title>. <source>J Virol</source>. <year>2002</year>
<month>1</month>;<volume>76</volume>(<issue>2</issue>):<fpage>707</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">11752161</pub-id></mixed-citation></ref><ref id="CIT0027"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abbas</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Herbein</surname><given-names>G</given-names></name></person-group>
<article-title>HIV-1 latency in monocytes/macrophages</article-title>. <source>Viruses</source>. <year>2014</year>
<month>4</month>
<day>22</day>;<volume>6</volume>(<issue>4</issue>):<fpage>1837</fpage>&#x02013;<lpage>1860</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">24759213</pub-id></mixed-citation></ref><ref id="CIT0028"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassol</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cassetta</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rizzi</surname><given-names>C</given-names></name>, et al</person-group>
<article-title>M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms</article-title>. <source>J Immunol</source>. <year>2009</year>
<month>5</month>
<day>15</day>;<volume>182</volume>(<issue>10</issue>):<fpage>6237</fpage>&#x02013;<lpage>6246</lpage>.<pub-id pub-id-type="pmid">19414777</pub-id></mixed-citation></ref><ref id="CIT0029"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbein</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Varin</surname><given-names>A</given-names></name></person-group>
<article-title>The macrophage in HIV-1 infection: from activation to deactivation?</article-title>
<source>Retrovirology</source>. <year>2010</year>
<month>4</month>
<day>9</day>;<volume>7</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">20380696</pub-id></mixed-citation></ref><ref id="CIT0030"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perno</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Svicher</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ceccherini-Silberstein</surname><given-names>F</given-names></name></person-group>
<article-title>Novel drug resistance mutations in HIV: recognition and clinical relevance</article-title>. <source>AIDS Rev</source>. <year>2006</year>
<season>Oct-Dec</season>;<volume>8</volume>(<issue>4</issue>):<fpage>179</fpage>&#x02013;<lpage>190</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">17219733</pub-id></mixed-citation></ref><ref id="CIT0031"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>XZ</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>TR</given-names></name>, et al</person-group>
<article-title>Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants</article-title>. <source>Retrovirology</source>. <year>2018</year>
<month>5</month>
<day>16</day>;<volume>15</volume>(<issue>1</issue>):<fpage>37</fpage>.<pub-id pub-id-type="pmid">29769116</pub-id></mixed-citation></ref><ref id="CIT0032"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name>, <name name-style="western"><surname>Staskus</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wietgrefe</surname><given-names>SW</given-names></name>, et al</person-group>
<article-title>Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>
<month>2</month>
<day>11</day>;<volume>111</volume>(<issue>6</issue>):<fpage>2307</fpage>&#x02013;<lpage>2312</lpage>.<pub-id pub-id-type="pmid">24469825</pub-id></mixed-citation></ref><ref id="CIT0033"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquaro</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Balestra</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cenci</surname><given-names>A</given-names></name>, et al</person-group>
<article-title>HIV infection in macrophage: role of long-lived cells and related therapeutical strategies</article-title>. <source>J Biol Regul Homeost Agents</source>. <year>1997</year>
<season>Jan-Jun</season>;<volume>11</volume>(<issue>1&#x02013;2</issue>):<fpage>69</fpage>&#x02013;<lpage>73</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">9418167</pub-id></mixed-citation></ref><ref id="CIT0034"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquaro</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cali&#x000f2;</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Balestra</surname><given-names>E</given-names></name>, et al</person-group>
<article-title>Clinical implications of HIV dynamics and drug resistance in macrophages</article-title>. <source>J Biol Regul Homeost Agents</source>. <year>1998</year>;<volume>12</volume>(<issue>1&#x02013;2 Suppl</issue>): <fpage>23</fpage>&#x02013;<lpage>27</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">9689575</pub-id></mixed-citation></ref><ref id="CIT0035"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarafianos</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Marchand</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>K</given-names></name>, et al</person-group>
<article-title>Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition</article-title>. <source>J Mol Biol</source>. <year>2009</year>
<month>1</month>
<day>23</day>;<volume>385</volume>(<issue>3</issue>):<fpage>693</fpage>&#x02013;<lpage>713</lpage>. <comment>Epub 2008 Nov 3. Review</comment>.<pub-id pub-id-type="pmid">19022262</pub-id></mixed-citation></ref><ref id="CIT0036"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orkin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Squires</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Molina</surname><given-names>JM</given-names></name>, et al. <collab>DRIVE-AHEAD Study Group</collab></person-group>
<article-title>Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial</article-title>. <source>Clin Infect Dis</source>. <year>2018</year>
<month>8</month><day>31</day> DOI:<pub-id pub-id-type="doi">10.1093/cid/ciy540</pub-id><comment>Epub ahead of print</comment></mixed-citation></ref><ref id="CIT0037"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darwish</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bond</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>R</given-names></name>, et al</person-group>
<article-title>Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults</article-title>. <source>Clin Ther</source>. <year>2015</year>
<month>2</month>
<day>1</day>;<volume>37</volume>(<issue>2</issue>):<fpage>325</fpage>&#x02013;<lpage>337</lpage>. <comment>Epub 2014 Oct 16</comment>.<pub-id pub-id-type="pmid">25438721</pub-id></mixed-citation></ref><ref id="CIT0038"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalilieh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>RI</given-names></name>, et al</person-group>
<article-title>Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>
<month>1</month>
<day>24</day>;<volume>61</volume>(<issue>2</issue>):<page-range>pii: e01364-16</page-range>
<comment>Print 2017 Feb</comment>.</mixed-citation></ref><ref id="CIT0039"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilby</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Eissa</surname><given-names>NA</given-names></name></person-group>
<article-title>Clinical Pharmacokinetics and Drug Interactions of Doravirine</article-title>. <source>Eur J Drug Metab Pharmacokinet</source>. <year>2018</year>
<month>7</month>
<day>25</day>
<comment>Epub ahead of print</comment> DOI:<pub-id pub-id-type="doi">10.1007/s13318-018-0497-3</pub-id></mixed-citation></ref><ref id="CIT0040"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalilieh</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>RI</given-names></name>, et al</person-group>
<article-title>Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects</article-title>. <source>J Clin Pharmacol</source>. <year>2018</year>
<month>5</month>
<day>3</day>
<comment>Epub ahead of print</comment> DOI:<pub-id pub-id-type="doi">10.1002/jcph.1103</pub-id></mixed-citation></ref><ref id="CIT0041"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Khalilieh</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>RI</given-names></name>, et al</person-group>
<article-title>The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects</article-title>. <source>Clin Drug Investig</source>. <year>2017</year>
<month>7</month>;<volume>37</volume>(<issue>7</issue>):<fpage>659</fpage>&#x02013;<lpage>667</lpage>.</mixed-citation></ref><ref id="CIT0042"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behm</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>R</given-names></name>, et al</person-group>
<article-title>The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects</article-title>. <source>Clin Drug Investig</source>. <year>2017</year>
<month>6</month>;<volume>37</volume>(<issue>6</issue>):<fpage>571</fpage>&#x02013;<lpage>579</lpage>.</mixed-citation></ref><ref id="CIT0043"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behm</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>L</given-names></name>, et al</person-group>
<article-title>Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects</article-title>. <comment>Epub 2017 Feb 16</comment>
<source>Antivir Ther</source>. <year>2017</year>;<volume>22</volume><issue>4</issue>:<fpage>337</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">28206979</pub-id></mixed-citation></ref><ref id="CIT0044"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Squires</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sax</surname><given-names>PE</given-names></name></person-group>, et al. <article-title>Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with hiv-1 (drive-forward): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial</article-title>. <source>Lancet Hiv</source>. <year>2020</year>
<month>1</month>;<volume>7</volume>(<issue>1</issue>):<fpage>e16-e26</fpage>.<pub-id pub-id-type="pmid">31740348</pub-id></mixed-citation></ref><ref id="CIT0045"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Michailidis</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schultz</surname><given-names>ML</given-names></name>, et al</person-group>
<article-title>SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>
<month>8</month>;<volume>58</volume>(<issue>8</issue>):<fpage>4915</fpage>&#x02013;<lpage>4919</lpage>.<pub-id pub-id-type="pmid">24867973</pub-id></mixed-citation></ref><ref id="CIT0046"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laguette</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rahm</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sobhian</surname><given-names>B</given-names></name>, et al</person-group>
<article-title>Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein</article-title>. <source>Cell Host Microbe</source>. <year>2012</year>
<month>2</month>
<day>16</day>;<volume>11</volume>(<issue>2</issue>):<fpage>205</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">22305291</pub-id></mixed-citation></ref><ref id="CIT0047"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mlcochova</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sutherland</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Watters</surname><given-names>SA</given-names></name>, et al</person-group>
<article-title>A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages</article-title>. <source>Embo J</source>. <year>2017</year>
<month>3</month>
<day>1</day>;<volume>36</volume>(<issue>5</issue>):<fpage>604</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="pmid">28122869</pub-id></mixed-citation></ref><ref id="CIT0048"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mlcochova</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Caswell</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>IA</given-names></name>, et al</person-group>
<article-title>DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages</article-title>. <source>Embo J</source>. <year>2018</year>
<month>1</month>
<day>4</day>;<volume>37</volume>(<issue>1</issue>):<fpage>50</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29084722</pub-id></mixed-citation></ref><ref id="CIT0049"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#x000e1;uregui</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Landau</surname><given-names>NR</given-names></name></person-group>
<article-title>DNA damage induces a SAMHD1-mediated block to the infection of macrophages by HIV-1</article-title>. <source>Sci Rep</source>. <year>2018</year>
<month>3</month>
<day>7</day>;<volume>8</volume>(<issue>1</issue>):<fpage>4153</fpage>.<pub-id pub-id-type="pmid">29515139</pub-id></mixed-citation></ref><ref id="CIT0050"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wensing</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>van Maarseveen</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Nijhuis</surname><given-names>M</given-names></name></person-group>
<article-title>Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance</article-title>. <source>Antiviral Res</source>. <year>2010</year>
<month>1</month>;<volume>85</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>74</lpage>. <comment>Epub 2009 Oct 22. Review</comment>.<pub-id pub-id-type="pmid">19853627</pub-id></mixed-citation></ref><ref id="CIT0051"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbaiah</surname><given-names>MAM</given-names></name>, <name name-style="western"><surname>Meanwell</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Kadow</surname><given-names>JF</given-names></name></person-group>
<article-title>Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties</article-title>. <source>Eur J Med Chem</source>. <year>2017</year>
<month>10</month>
<day>20</day>;<volume>139</volume>:<fpage>865</fpage>&#x02013;<lpage>883</lpage>.<pub-id pub-id-type="pmid">28865281</pub-id></mixed-citation></ref><ref id="CIT0052"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pommier</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Marchand</surname><given-names>C</given-names></name></person-group>
<article-title>Integrase inhibitors to treat HIV/AIDS</article-title>. <source>Nat Rev Drug Discov</source>. <year>2005</year>
<month>3</month>;<volume>4</volume>(<issue>3</issue>):<fpage>236</fpage>&#x02013;<lpage>248</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">15729361</pub-id></mixed-citation></ref><ref id="CIT0053"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsurutani</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kubo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Maeda</surname><given-names>Y</given-names></name>, et al</person-group>
<article-title>Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells</article-title>. <source>J Virol</source>. <year>2000</year>
<month>5</month>;<volume>74</volume>(<issue>10</issue>):<fpage>4795</fpage>&#x02013;<lpage>4806</lpage>.<pub-id pub-id-type="pmid">10775618</pub-id></mixed-citation></ref><ref id="CIT0054"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Dobard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>SA</given-names></name></person-group>
<article-title>Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase</article-title>. <source>J Virol</source>. <year>2004</year>
<month>5</month>;<volume>78</volume>(<issue>10</issue>):<fpage>5045</fpage>&#x02013;<lpage>5055</lpage>.<pub-id pub-id-type="pmid">15113886</pub-id></mixed-citation></ref><ref id="CIT0055"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scopelliti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pollicita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ceccherini-Silberstein</surname><given-names>F</given-names></name>, et al</person-group>
<article-title>Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes</article-title>. <source>Antiviral Res</source>. <year>2011</year>
<month>11</month>;<volume>92</volume>(<issue>2</issue>):<fpage>255</fpage>&#x02013;<lpage>261</lpage>. <comment>Epub 2011 Aug 16</comment>.<pub-id pub-id-type="pmid">21867733</pub-id></mixed-citation></ref><ref id="CIT0056"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollicita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Surdo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Di Santo</surname><given-names>F</given-names></name>, et al</person-group>
<article-title>Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes</article-title>. <source>J Antimicrob Chemother</source>. <year>2014</year>
<month>9</month>;<volume>69</volume>(<issue>9</issue>):<fpage>2412</fpage>&#x02013;<lpage>2419</lpage>. <comment>Epub 2014 May 23</comment>.<pub-id pub-id-type="pmid">24860155</pub-id></mixed-citation></ref><ref id="CIT0057"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshinaga</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Seki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miki</surname><given-names>S</given-names></name>, et al</person-group>
<article-title>Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors</article-title>. <source>Antiviral Res</source>. <year>2018</year><month>4</month>;<volume>152</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29410019</pub-id></mixed-citation></ref><ref id="CIT0058"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neogi</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Aralaguppe</surname><given-names>SG</given-names></name>, et al</person-group>
<article-title>Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes</article-title>. <source>AIDS</source>. <year>2018</year>
<month>2</month>
<day>20</day>;<volume>32</volume>(<issue>4</issue>):<fpage>469</fpage>&#x02013;<lpage>476</lpage>.<pub-id pub-id-type="pmid">29239896</pub-id></mixed-citation></ref><ref id="CIT0059"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalezari</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>DeJesus</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Northfelt</surname><given-names>DW</given-names></name>, et al</person-group>
<article-title>A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults</article-title>. <source>Antivir Ther</source>. <year>2003</year>
<day>8</day>
<volume>Aug</volume>(<issue>4</issue>):<fpage>279</fpage>&#x02013;<lpage>287</lpage>.</mixed-citation></ref><ref id="CIT0060"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eron</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Gulick</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Bartlett</surname><given-names>JA</given-names></name>, et al</person-group>
<article-title>Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV</article-title>. <source>J Infect Dis</source>. <year>2004</year>
<month>3</month>
<day>15</day>;<volume>189</volume>(<issue>6</issue>):<fpage>1075</fpage>&#x02013;<lpage>1083</lpage>. <comment>Epub 2004 Mar 2</comment>.<pub-id pub-id-type="pmid">14999611</pub-id></mixed-citation></ref><ref id="CIT0061"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalezari</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name>, et al</person-group>
<article-title>Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults</article-title>. <source>AIDS</source>. <year>2005</year>
<month>9</month>
<day>23</day>;<volume>19</volume>(<issue>14</issue>):<fpage>1443</fpage>&#x02013;<lpage>1448</lpage>.<pub-id pub-id-type="pmid">16135896</pub-id></mixed-citation></ref><ref id="CIT0062"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwyer</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Davison</surname><given-names>DK</given-names></name>, et al</person-group>
<article-title>Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>
<month>7</month>
<day>31</day>;<volume>104</volume>(<issue>31</issue>):<fpage>12772</fpage>&#x02013;<lpage>12777</lpage>. <comment>Epub 2007 Jul 19</comment>.<pub-id pub-id-type="pmid">17640899</pub-id></mixed-citation></ref><ref id="CIT0063"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>H</given-names></name>, et al</person-group>
<article-title>Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2008</year>
<month>10</month>
<day>21</day>;<volume>105</volume>(<issue>42</issue>):<fpage>16332</fpage>&#x02013;<lpage>16337</lpage>. <comment>Epub 2008 Oct 13</comment>.<pub-id pub-id-type="pmid">18852475</pub-id></mixed-citation></ref><ref id="CIT0064"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reeves</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Gallo</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>N</given-names></name>, et al</person-group>
<article-title>Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2002</year>
<month>12</month>
<day>10</day>;<volume>99</volume>(<issue>25</issue>):<fpage>16249</fpage>&#x02013;<lpage>16254</lpage>. <comment>Epub 2002 Nov 20</comment>.<pub-id pub-id-type="pmid">12444251</pub-id></mixed-citation></ref><ref id="CIT0065"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mink</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mosier</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Janumpalli</surname><given-names>S</given-names></name>, et al</person-group>
<article-title>Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro</article-title>. <source>J Virol</source>. <year>2005</year>
<month>10</month>;<volume>79</volume>(<issue>19</issue>):<fpage>12447</fpage>&#x02013;<lpage>12454</lpage>.<pub-id pub-id-type="pmid">16160172</pub-id></mixed-citation></ref><ref id="CIT0066"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Decker</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, et al</person-group>
<article-title>Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2002</year>
<month>6</month>;<volume>46</volume>(<issue>6</issue>):<fpage>1896</fpage>&#x02013;<lpage>1905</lpage>.<pub-id pub-id-type="pmid">12019106</pub-id></mixed-citation></ref><ref id="CIT0067"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Hazuda</surname><given-names>DJ</given-names></name></person-group>
<article-title>HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications</article-title>. <source>Drug Resist Updat</source>. <year>2004</year>
<month>4</month>;<volume>7</volume>(<issue>2</issue>):<fpage>89</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">15158765</pub-id></mixed-citation></ref><ref id="CIT0068"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reeves</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Miamidian</surname><given-names>JL</given-names></name>, et al</person-group>
<article-title>Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization</article-title>. <source>J Virol</source>. <year>2005</year>
<month>4</month>;<volume>79</volume>(<issue>8</issue>):<fpage>4991</fpage>&#x02013;<lpage>4999</lpage>.<pub-id pub-id-type="pmid">15795284</pub-id></mixed-citation></ref><ref id="CIT0069"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquaro</surname><given-names>S</given-names></name>, <name name-style="western"><surname>D&#x02019;Arrigo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Svicher</surname><given-names>V</given-names></name>, et al</person-group>
<article-title>Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment</article-title>. <source>J Antimicrob Chemother</source>. <year>2006</year>
<month>10</month>;<volume>58</volume>(<issue>4</issue>):<fpage>714</fpage>&#x02013;<lpage>722</lpage>. <comment>Epub 2006 Aug 5</comment>.<pub-id pub-id-type="pmid">16891628</pub-id></mixed-citation></ref><ref id="CIT0070"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cammack</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Salgo</surname><given-names>M</given-names></name>, et al</person-group>
<article-title>HIV fusion and its inhibition in antiretroviral therapy</article-title>. <source>Rev Med Virol</source>. <year>2004</year>
<comment>Sep-Oct</comment>; <volume>14</volume> (<issue>5</issue>): <fpage>321</fpage>&#x02013;<lpage>337</lpage>. <comment>Review</comment>;():.<pub-id pub-id-type="pmid">15334539</pub-id></mixed-citation></ref><ref id="CIT0071"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alessandri-Gradt</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Charpentier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Leoz</surname><given-names>M</given-names></name>, et al</person-group>
<article-title>Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir</article-title>. <source>J Antimicrob Chemother</source>. <year>2018</year>
<month>10</month>
<day>1</day>;<volume>73</volume>(<issue>10</issue>):<fpage>2716</fpage>&#x02013;<lpage>2720</lpage>.<pub-id pub-id-type="pmid">30032194</pub-id></mixed-citation></ref><ref id="CIT0072"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Sch&#x000fc;rmann</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name>, et al</person-group>
<article-title>Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects</article-title>. <source>J Infect Dis</source>. <year>2012</year>
<month>10</month>
<day>1</day>;<volume>206</volume>(<issue>7</issue>):<fpage>1002</fpage>&#x02013;<lpage>1011</lpage>. <comment>Epub 2012 Aug 14</comment>.<pub-id pub-id-type="pmid">22896665</pub-id></mixed-citation></ref><ref id="CIT0073"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalezari</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Latiff</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Brinson</surname><given-names>C</given-names></name>, et al., <collab>AI438011 study team</collab></person-group>
<article-title>Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial</article-title>. <source>Lancet HIV</source>. <year>2015</year>
<month>10</month>
<day>2</day>;<issue>10</issue>:<fpage>e427</fpage>&#x02013;<lpage>37</lpage>. DOI:<pub-id pub-id-type="doi">10.1016/S2352-3018(15)00177-0</pub-id>
<comment>Epub 2015 Sep 1</comment><pub-id pub-id-type="pmid">26423650</pub-id></mixed-citation></ref><ref id="CIT0074"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lalezari</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>R</given-names></name>, et al., <collab>AI438011 study team</collab></person-group>
<article-title>Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial</article-title>. <source>Antivir Ther</source>. <year>2017</year>;<volume>22</volume>(<issue>3</issue>):<fpage>215</fpage>&#x02013;<lpage>223</lpage>. <comment>Epub 2016 Dec 6</comment><pub-id pub-id-type="pmid">27922453</pub-id></mixed-citation></ref><ref id="CIT0075"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragic</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Trkola</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>DA</given-names></name>, et al</person-group>
<article-title>A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2000</year>
<month>5</month>
<day>9</day>;<volume>97</volume>(<issue>10</issue>):<fpage>5639</fpage>&#x02013;<lpage>5644</lpage>.<pub-id pub-id-type="pmid">10779565</pub-id></mixed-citation></ref><ref id="CIT0076"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Momboisse</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Boncompain</surname><given-names>G</given-names></name>, et al</person-group>
<article-title>CCR5 adopts three homodimeric conformations that control cell surface delivery</article-title>. <source>Sci Signal</source>. <year>2018</year>
<month>5</month>
<day>8</day>;<volume>11</volume>(<issue>529</issue>):<page-range>pii: eaal2869</page-range>.</mixed-citation></ref><ref id="CIT0077"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Perez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rueda</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Alcami</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5)</article-title>. <source>J Biol Chem</source>. <year>2011</year>
<month>9</month>
<day>23</day>;<volume>286</volume>(<issue>38</issue>):<fpage>33409</fpage>&#x02013;<lpage>33421</lpage>. <comment>Epub 2011 Jul 20</comment>.<pub-id pub-id-type="pmid">21775441</pub-id></mixed-citation></ref><ref id="CIT0078"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Perez J</surname></name>, <name name-style="western"><surname>Rueda</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Staropoli</surname><given-names>I</given-names></name>, et al</person-group>
<article-title>New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection</article-title>. <source>J Biol Chem</source>. <year>2011</year>
<month>2</month>
<day>18</day>;<volume>286</volume>(<issue>7</issue>):<fpage>4978</fpage>&#x02013;<lpage>4990</lpage>. <comment>Epub 2010 Nov 30</comment>.<pub-id pub-id-type="pmid">21118814</pub-id></mixed-citation></ref><ref id="CIT0079"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westby</surname><given-names>M</given-names></name>, <name name-style="western"><surname>van der Ryst</surname><given-names>E</given-names></name></person-group>
<article-title>CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on</article-title>. <source>Antivir Chem Chemother</source>. <year>2010</year>
<month>4</month>
<day>14</day>;<volume>20</volume>(<issue>5</issue>):<fpage>179</fpage>&#x02013;<lpage>192</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">20413825</pub-id></mixed-citation></ref><ref id="CIT0080"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westby</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Smith-Burchnell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry</article-title>. <source>J Virol</source>. <year>2007</year>
<month>3</month>;<volume>81</volume>(<issue>5</issue>):<fpage>2359</fpage>&#x02013;<lpage>2371</lpage>. <comment>Epub 2006 Dec 20</comment>.<pub-id pub-id-type="pmid">17182681</pub-id></mixed-citation></ref><ref id="CIT0081"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roche</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jakobsen</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Ellett</surname><given-names>A</given-names></name>, et al</person-group>
<article-title>HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry</article-title>. <source>Retrovirology</source>. <year>2011</year>
<month>11</month>
<day>7</day>;<volume>8</volume>: <fpage>89</fpage>.<pub-id pub-id-type="pmid">22054077</pub-id></mixed-citation></ref><ref id="CIT0082"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tilton</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Wilen</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Didigu</surname><given-names>CA</given-names></name>, et al</person-group>
<article-title>A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5</article-title>. <source>J Virol</source>. <year>2010</year>
<month>10</month>;<volume>84</volume>(<issue>20</issue>):<fpage>10863</fpage>&#x02013;<lpage>10876</lpage>. <comment>Epub 2010 Aug 11</comment>.<pub-id pub-id-type="pmid">20702642</pub-id></mixed-citation></ref><ref id="CIT0083"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuzin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Trabelsi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Delobel</surname><given-names>P</given-names></name>, et al.,<collab>ANRS 145 MARIMUNO Study group</collab></person-group>
<article-title>Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2012</year>
<month>12</month>
<day>15</day>; <volume>61</volume>: <issue>5</issue>
<fpage>557</fpage>&#x02013;<lpage>564</lpage>.<pub-id pub-id-type="pmid">22986949</pub-id></mixed-citation></ref><ref id="CIT0084"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunt</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Shulman</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>TL</given-names></name>, et al</person-group>
<article-title>The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial</article-title>. <source>Blood</source>. <year>2013</year>
<month>6</month>
<day>6</day>;<volume>121</volume>(<issue>23</issue>):<fpage>4635</fpage>&#x02013;<lpage>4646</lpage>. <comment>Epub 2013 Apr 15</comment>.<pub-id pub-id-type="pmid">23589670</pub-id></mixed-citation></ref><ref id="CIT0085"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ananworanich</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chomont</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Fletcher</surname><given-names>JL</given-names></name>, et al</person-group>
<article-title>Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification</article-title>. <source>J Virus Erad</source>. <year>2015</year>;<volume>1</volume>(<issue>2</issue>):<fpage>116</fpage>&#x02013;<lpage>122</lpage>. <comment>Epub 2015 Apr 1</comment>.<pub-id pub-id-type="pmid">26835516</pub-id></mixed-citation></ref><ref id="CIT0086"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cillo</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Hilldorfer</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Lalama</surname><given-names>CM</given-names></name>, et al</person-group>
<article-title>Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery</article-title>. <source>AIDS</source>. <year>2015</year>
<month>10</month>
<day>23</day>;<volume>29</volume>(<issue>16</issue>):<fpage>2121</fpage>&#x02013;<lpage>2129</lpage>.<pub-id pub-id-type="pmid">26544577</pub-id></mixed-citation></ref><ref id="CIT0087"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Lelyveld</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Drylewicz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Krikke</surname><given-names>M</given-names></name>, et al.; <collab>MIRS study group</collab></person-group>
<article-title>Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial</article-title>. <source>PLoS One</source>. <year>2015</year>
<month>7</month>
<day>24</day>;<volume>10</volume>(<issue>7</issue>):<fpage>e0132430</fpage>
<comment>eCollection 2015</comment>.<pub-id pub-id-type="pmid">26208341</pub-id></mixed-citation></ref><ref id="CIT0088"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ch&#x000e9;ret</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nembot</surname><given-names>G</given-names></name>, <name name-style="western"><surname>M&#x000e9;lard</surname><given-names>A</given-names></name>, et al</person-group>
<article-title>Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial</article-title>. <source>Lancet Infect Dis</source>. <year>2015</year>
<month>4</month>;<volume>15</volume>(<issue>4</issue>):<fpage>387</fpage>&#x02013;<lpage>396</lpage>. <comment>Epub 2015 Feb 18</comment>.<pub-id pub-id-type="pmid">25701561</pub-id></mixed-citation></ref><ref id="CIT0089"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ablan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Freed</surname><given-names>EO</given-names></name>, et al</person-group>
<article-title>Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity</article-title>. <source>J Virol</source>. <year>2004</year>
<month>1</month>;<volume>78</volume>(<issue>2</issue>):<fpage>1026</fpage>&#x02013;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">14694135</pub-id></mixed-citation></ref><ref id="CIT0090"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surdo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Balestra</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Saccomandi</surname><given-names>P</given-names></name>, et al</person-group>
<article-title>Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages</article-title>. <source>PLoS One</source>. <year>2013</year>
<month>7</month>
<day>9</day>;<volume>8</volume>(<issue>7</issue>):<fpage>e68076</fpage>
<comment>Print 2013</comment>.<pub-id pub-id-type="pmid">23874501</pub-id></mixed-citation></ref><ref id="CIT0091"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borrajo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ranazzi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pollicita</surname><given-names>M</given-names></name>, et al</person-group>
<article-title>Different patterns of HIV-1 replication in MACROPHAGES is led by co-receptor usage</article-title>. <source>Medicina (Kaunas)</source>. <year>2019</year>
<month>6</month>
<day>21</day>;<volume>55</volume>(<issue>6</issue>):<page-range>pii: E297</page-range>.</mixed-citation></ref><ref id="CIT0092"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamson</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Ablan</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Boeras</surname><given-names>I</given-names></name>, et al</person-group>
<article-title>In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)</article-title>. <source>J Virol</source>. <year>2006</year>
<month>11</month>;<volume>80</volume>(<issue>22</issue>):<fpage>10957</fpage>&#x02013;<lpage>10971</lpage>. <comment>Epub 2006 Sep 6</comment>.<pub-id pub-id-type="pmid">16956950</pub-id></mixed-citation></ref><ref id="CIT0093"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Dismuke</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation</article-title>. <source>J Virol</source>. <year>2004</year>
<month>1</month>;<volume>78</volume>(<issue>2</issue>):<fpage>922</fpage>&#x02013;<lpage>929</lpage>.<pub-id pub-id-type="pmid">14694123</pub-id></mixed-citation></ref><ref id="CIT0094"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freed</surname><given-names>EO</given-names></name></person-group>
<article-title>HIV-1 assembly, release and maturation</article-title>. <source>Nat Rev Microbiol</source>. <year>2015</year>
<month>8</month>;<volume>13</volume>(<issue>8</issue>):<fpage>484</fpage>&#x02013;<lpage>496</lpage>. <comment>Epub 2015 Jun 29. Review</comment>.<pub-id pub-id-type="pmid">26119571</pub-id></mixed-citation></ref><ref id="CIT0095"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Potempa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Swanstrom</surname><given-names>R</given-names></name></person-group>
<article-title>The choreography of HIV-1 proteolytic processing and virion assembly</article-title>. <source>J Biol Chem</source>. <year>2012</year>
<month>11</month>
<day>30</day>;<volume>287</volume>(<issue>49</issue>):<fpage>40867</fpage>&#x02013;<lpage>40874</lpage>. <comment>Epub 2012 Oct 5. Review</comment>.<pub-id pub-id-type="pmid">23043111</pub-id></mixed-citation></ref><ref id="CIT0096"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urano</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ablan</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Mandt</surname><given-names>R</given-names></name>, et al</person-group>
<article-title>Alkyl amine bevirimat derivatives are potent and broadly active HIV-1 maturation inhibitors</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>
<month>10</month>
<day>19</day>;<volume>60</volume>(<issue>1</issue>):<fpage>190</fpage>&#x02013;<lpage>197</lpage>. <comment>Print 2016 Jan</comment>.<pub-id pub-id-type="pmid">26482309</pub-id></mixed-citation></ref><ref id="CIT0097"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spearman</surname><given-names>P</given-names></name></person-group>
<article-title>HIV-1 gag as an antiviral target: development of assembly and maturation inhibitors</article-title>. <source>Curr Top Med Chem</source>. <year>2016</year>;<volume>16</volume>(<issue>10</issue>): <fpage>1154</fpage>&#x02013;<lpage>1166</lpage>. <comment>Review</comment>.<pub-id pub-id-type="pmid">26329615</pub-id></mixed-citation></ref><ref id="CIT0098"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundquist</surname><given-names>WI</given-names></name>, <name name-style="western"><surname>Kr&#x000e4;usslich</surname><given-names>HG</given-names></name></person-group>
<article-title>HIV-1 assembly, budding, and maturation</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2012</year>
<month>7</month>;<volume>2</volume>(<issue>7</issue>):<fpage>a006924</fpage> DOI:. <comment>Review. Erratum in: Cold Spring Harb Perspect Med. 2012 Aug; 2 (8)</comment>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a015420</pub-id>.<pub-id pub-id-type="pmid">22762019</pub-id></mixed-citation></ref><ref id="CIT0099"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyma</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail</article-title>. <source>J Virol</source>. <year>2004</year>
<month>4</month>;<volume>78</volume>(<issue>7</issue>):<fpage>3429</fpage>&#x02013;<lpage>3435</lpage>.<pub-id pub-id-type="pmid">15016865</pub-id></mixed-citation></ref><ref id="CIT0100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Checkley</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Luttge</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Soheilian</surname><given-names>F</given-names></name>, et al</person-group>
<article-title>The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation</article-title>. <source>Virology</source>. <year>2010</year>
<month>4</month>
<day>25</day>;<volume>400</volume>(<issue>1</issue>):<fpage>137</fpage>&#x02013;<lpage>144</lpage>. <comment>Epub 2010 Feb 20</comment>.<pub-id pub-id-type="pmid">20172577</pub-id></mixed-citation></ref><ref id="CIT0101"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Swanstrom</surname><given-names>R</given-names></name></person-group>
<article-title>A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle</article-title>. <source>J Virol</source>. <year>2009</year>
<month>9</month>;<volume>83</volume>(<issue>17</issue>):<fpage>8536</fpage>&#x02013;<lpage>8543</lpage>.<pub-id pub-id-type="pmid">19515760</pub-id></mixed-citation></ref><ref id="CIT0102"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#x000fc;ller</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Anders</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Akiyama</surname><given-names>H</given-names></name>, et al</person-group>
<article-title>HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity</article-title>. <source>J Biol Chem</source>. <year>2009</year>
<month>10</month>
<day>23</day>;<volume>284</volume>(<issue>43</issue>):<fpage>29692</fpage>&#x02013;<lpage>29703</lpage>. <comment>Epub 2009 Aug 7</comment>.<pub-id pub-id-type="pmid">19666477</pub-id></mixed-citation></ref><ref id="CIT0103"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name></person-group>
<article-title>Pharmacological intervention of HIV-1 maturation</article-title>. <source>Acta Pharm Sin B</source>. <year>2015</year>
<month>11</month>
<day>5</day>;(<issue>6</issue>):<fpage>493</fpage>&#x02013;<lpage>499</lpage>. <comment>Epub 2015 Jun 11. Review</comment> Doi:<pub-id pub-id-type="doi">10.1016/j.apsb.2015.05.004</pub-id><pub-id pub-id-type="pmid">26713265</pub-id></mixed-citation></ref><ref id="CIT0104"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zoumplis</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Matallana</surname><given-names>C</given-names></name>, et al</person-group>
<article-title>Determinants of activity of the HIV-1 maturation inhibitor PA-457</article-title>. <source>Virology</source>. <year>2006</year>
<month>12</month>
<day>5-20</day>;<volume>356</volume>(<issue>1&#x02013;2</issue>):<fpage>217</fpage>&#x02013;<lpage>224</lpage>. <comment>Epub 2006 Aug 22</comment>.<pub-id pub-id-type="pmid">16930665</pub-id></mixed-citation></ref><ref id="CIT0105"><label>[105]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Aiken</surname><given-names>C</given-names></name></person-group>
<article-title>Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3&#x002b9;,3&#x002b9;-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag</article-title>. <source>J Virol</source>. <year>2006</year>
<month>12</month>;<volume>80</volume>(<issue>24</issue>):<fpage>12095</fpage>&#x02013;<lpage>12101</lpage>. <comment>Epub 2006 Oct 11</comment>.<pub-id pub-id-type="pmid">17035324</pub-id></mixed-citation></ref><ref id="CIT0106"><label>[106]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Aiken</surname><given-names>C</given-names></name></person-group>
<article-title>The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3&#x002b9;,3&#x002b9;-dimethylsuccinyl}-betulinic acid</article-title>. <source>Retrovirology</source>. <year>2004</year>
<month>6</month>
<day>29</day>;<volume>1</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">15225375</pub-id></mixed-citation></ref><ref id="CIT0107"><label>[107]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hachey</surname><given-names>DL</given-names></name>, et al</person-group>
<article-title>Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles</article-title>. <source>J Biol Chem</source>. <year>2005</year>
<month>12</month>
<day>23</day>;<volume>280</volume>(<issue>51</issue>):<fpage>42149</fpage>&#x02013;<lpage>42155</lpage>. <comment>Epub 2005 Oct 25</comment>.<pub-id pub-id-type="pmid">16251182</pub-id></mixed-citation></ref><ref id="CIT0108"><label>[108]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowicka-Sans</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Protack</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name>, et al</person-group>
<article-title>Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and gag polymorphic coverage</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2016</year>
<month>6</month>
<day>20</day>;<volume>60</volume>(<issue>7</issue>):<fpage>3956</fpage>&#x02013;<lpage>3969</lpage>. <comment>Print 2016 Jul</comment>.<pub-id pub-id-type="pmid">27090171</pub-id></mixed-citation></ref><ref id="CIT0109"><label>[109]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regueiro-Ren</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, et al</person-group>
<article-title>Discovery of BMS-955176, a second generation HIV-1 maturation inhibitor with broad spectrum antiviral activity</article-title>. <source>ACS Med Chem Lett</source>. <year>2016</year>
<month>4</month>
<day>22</day>;<volume>7</volume>(<issue>6</issue>):<fpage>568</fpage>&#x02013;<lpage>572</lpage>. <comment>eCollection 2016 Jun 9</comment>.<pub-id pub-id-type="pmid">27326328</pub-id></mixed-citation></ref><ref id="CIT0110"><label>[110]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name>, et al</person-group>
<article-title>The second-generation maturation inhibitor GSK3532795 maintains potent activity toward HIV protease inhibitor-resistant clinical isolates</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2017</year>
<month>5</month>
<day>1</day>;<volume>75</volume>(<issue>1</issue>):<fpage>52</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">28234686</pub-id></mixed-citation></ref><ref id="CIT0111"><label>[111]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadowski</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hashemi</surname><given-names>FB</given-names></name></person-group>
<article-title>Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs</article-title>. <source>Cell Mol Life Sci</source>. <year>2019</year>
<month>9</month>;<volume>76</volume>(<issue>18</issue>):<fpage>3583</fpage>&#x02013;<lpage>3600</lpage>. <comment>Epub 2019 May 25. Review</comment>.<pub-id pub-id-type="pmid">31129856</pub-id></mixed-citation></ref><ref id="CIT0112"><label>[112]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lusic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Giacca</surname><given-names>M</given-names></name></person-group>
<article-title>Regulation of HIV-1 latency by chromatin structure and nuclear architecture</article-title>. <source>J Mol Biol</source>. <year>2015</year>
<month>2</month>
<day>13</day>;<volume>427</volume>(<issue>3</issue>):<fpage>688</fpage>&#x02013;<lpage>694</lpage>. <comment>Epub 2014 Jul 27. Review</comment>.<pub-id pub-id-type="pmid">25073101</pub-id></mixed-citation></ref><ref id="CIT0113"><label>[113]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamamis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Floudas</surname><given-names>CA</given-names></name></person-group>
<article-title>Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop</article-title>. <source>PLoS One</source>. <year>2014</year>
<month>4</month>
<day>24</day>;<volume>9</volume>(<issue>4</issue>):<fpage>e95767</fpage>
<comment>eCollection 2014</comment>.<pub-id pub-id-type="pmid">24763408</pub-id></mixed-citation></ref><ref id="CIT0114"><label>[114]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowacek</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>McMillan</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery</article-title>. <source>Nanomedicine (Lond)</source>. <year>2009</year>
<month>12</month>;<volume>4</volume>(<issue>8</issue>):<fpage>903</fpage>&#x02013;<lpage>917</lpage>.<pub-id pub-id-type="pmid">19958227</pub-id></mixed-citation></ref><ref id="CIT0115"><label>[115]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rossi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fraternale</surname><given-names>A</given-names></name>, et al</person-group>
<article-title>Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5&#x002b9;-triphosphate-loaded erythrocytes</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>1994</year>
<month>9</month>;<volume>10</volume>(<issue>9</issue>):<fpage>1179</fpage>&#x02013;<lpage>1186</lpage>.<pub-id pub-id-type="pmid">7826702</pub-id></mixed-citation></ref><ref id="CIT0116"><label>[116]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Grotepas</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>McMillan</surname><given-names>JM</given-names></name>, et al</person-group>
<article-title>Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS</article-title>. <source>J Immunol</source>. <year>2009</year>
<month>7</month>
<day>1</day>;<volume>183</volume>(<issue>1</issue>):<fpage>661</fpage>&#x02013;<lpage>669</lpage>. <comment>Epub 2009 Jun 17</comment>.<pub-id pub-id-type="pmid">19535632</pub-id></mixed-citation></ref><ref id="CIT0117"><label>[117]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Skinner</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Veerubhotla</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, et al</person-group>
<article-title>Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity</article-title>. <source>J Proteome Res</source>. <year>2013</year>
<month>5</month>
<day>3</day>;<volume>12</volume>(<issue>5</issue>):<fpage>2282</fpage>&#x02013;<lpage>2294</lpage>.<pub-id pub-id-type="pmid">23544708</pub-id></mixed-citation></ref><ref id="CIT0118"><label>[118]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aouadi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tesz</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Nicoloro</surname><given-names>SM</given-names></name>, et al</person-group>
<article-title>Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation</article-title>. <source>Nature</source>. <year>2009</year>
<month>4</month>
<day>30</day>;<volume>458</volume>(<issue>7242</issue>):<fpage>1180</fpage>&#x02013;<lpage>1184</lpage>.<pub-id pub-id-type="pmid">19407801</pub-id></mixed-citation></ref><ref id="CIT0119"><label>[119]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Prevedel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Eugenin</surname><given-names>EA</given-names></name></person-group>
<article-title>HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim</article-title>. <source>Sci Rep</source>. <year>2017</year>
<month>10</month>
<day>9</day>;<volume>7</volume>(<issue>1</issue>):<fpage>12866</fpage>.<pub-id pub-id-type="pmid">28993666</pub-id></mixed-citation></ref><ref id="CIT0120"><label>[120]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Prevedel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Valdebenito</surname><given-names>S</given-names></name>, et al</person-group>
<article-title>HIV infection and latency induce a unique metabolic signature in human macrophages</article-title>. <source>Sci Rep</source>. <year>2019</year>
<month>3</month>
<day>8</day>;<volume>9</volume>(<issue>1</issue>):<fpage>3941</fpage>.<pub-id pub-id-type="pmid">30850623</pub-id></mixed-citation></ref><ref id="CIT0121"><label>[121]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganor</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Real</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sennepin</surname><given-names>A</given-names></name>, et al</person-group>
<article-title>HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy</article-title>. <source>Nat Microbiol</source>. <year>2019</year>
<day>4</day>;<volume>Apr</volume>(<issue>4</issue>):<fpage>633</fpage>&#x02013;<lpage>644</lpage>.</mixed-citation></ref></ref-list></back></article>